HealthInvest Partners AB Invests $3.50 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

HealthInvest Partners AB bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,979 shares of the biopharmaceutical company’s stock, valued at approximately $3,495,000. Regeneron Pharmaceuticals accounts for about 2.8% of HealthInvest Partners AB’s holdings, making the stock its 18th largest holding.

Other hedge funds have also made changes to their positions in the company. Sunbelt Securities Inc. purchased a new position in Regeneron Pharmaceuticals during the first quarter worth about $25,000. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter worth about $26,000. Fortitude Family Office LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $31,000. Sutton Wealth Advisors Inc. increased its holdings in Regeneron Pharmaceuticals by 38.2% in the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 13 shares in the last quarter. Finally, Bruce G. Allen Investments LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $40,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,729 shares of company stock worth $13,124,641. Company insiders own 8.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on REGN. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. Cantor Fitzgerald reissued a “neutral” rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday. Finally, StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $970.57.

Regeneron Pharmaceuticals Trading Down 0.5 %

Shares of REGN traded down $4.42 during trading hours on Tuesday, hitting $894.14. The stock had a trading volume of 615,755 shares, compared to its average volume of 495,922. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $998.33. The firm has a market cap of $98.14 billion, a P/E ratio of 25.86, a P/E/G ratio of 2.64 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The company’s fifty day simple moving average is $956.81 and its 200 day simple moving average is $889.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same period in the prior year, the firm posted $10.96 earnings per share. The firm’s revenue was up .6% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.18 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.